Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. reported a net loss of $17.9 million for fiscal year 2025, an improvement from a $76.6 million loss in 2024. Total revenue grew significantly to $35.6 million, driven by $15.3 million in product revenue from YCANTH (VP-102) and $20.3 million in license and collaboration revenue, primarily from milestone payments from Torii. Operating expenses totaled $47.8 million, with selling, general and administrative costs of $35.2 million and research and development expenses of $8.9 million. The company ended the year with $30.1 million in cash and cash equivalents, a decrease of $16.2 million from the prior year, and an accumulated deficit of $324.9 million. The financial statements include a going concern qualification, indicating substantial doubt about the company's ability to continue as a going concern within one year.

Key Takeaways